Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: Phase II randomized study comparing two dose levels

Cancer Gene Therapy

Volumn 9, Issue 3, 2002, Pages 289-295

  Rochlitz, Christoph ^a   Dreno, Brigitte ^b   Jantscheff, Peter ^a   Cavalli, Franco ^c   Squiban, Patrick ^d   Acres, Bruce ^d   Baudin, Martine ^d   Escudier, Bernard ^e   Heinzerling, Lucie ^h   Morant, Rudolf ^f   Herrmann, Richard ^a   Dietrich, Pierre Yves ^g   Dummer, Reinhard ^h  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b HÔTEL DIEU   (France)

^c OSPEDALE SAN GIOVANNI   (Switzerland)

^d Transène   (Switzerland)

^e IGR   (France)

^f CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^g UNIVERSITY HOSPITAL   (Switzerland)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Cancer gene therapy; IL 2; Immunotherapy; Melanoma; Xenogeneic cells

Indexed keywords

ADULT; AGED; ANIMALS; CERCOPITHECUS AETHIOPS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNITY; IMMUNOTHERAPY; INJECTIONS, INTRALESIONAL; INTERLEUKIN-2; MALE; MELANOMA; MIDDLE AGED; NEOPLASMS; RNA, MESSENGER; T-LYMPHOCYTES; TRANSPLANTATION, HETEROLOGOUS; TREATMENT OUTCOME; VERO CELLS;

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; TG 2001; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; FEMALE; FEVER; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INJECTION SITE; MALE; MELANOMA; METASTASIS; PAIN; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; TUMOR BIOPSY; TUMOR REGRESSION; VERO CELL; XENOGRAFT;

ANIMALIA;

EID: 85047699623     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700441     Document Type: Article

References (42)

1. Murine interleukin-4 displays potent antitumor activity in vivo
2. Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity
3. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity
4. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response
5. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4
6. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, long-lasting anti-tumor immunity
7. Immune response against tumors
8. Immunological gene therapy with ex vivo gene-modified tumor cells: A critique and a reappraisal
9. Inhibition of tumor growth by histoincompatible cells expressing interleukin-2
10. Gene therapy of spontaneous canine melanoma and feline fibrosarcoma by intratumoral administration of histoincompatible cells expressing human interleukin-2
11. Gene therapy study of cytokine-transfected xenogeneic cells (Vero-interleukin-2) in patients with metastatic solid tumors
12. Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: Clinical and immunological findings
13. P21 gene expression as an indicator for the activity of adenovirus-p53 gene therapy in non-small cell lung cancer patients
14. Increased non-major histocompatibility complex-restricted lytic activity in melanoma patients vaccinated with cytokine gene-transfected autologous tumor cells
15. Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor
16. Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells
17. Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma
18. Phase I study of chemokine and cytokine gene-modified autologous neuroblastoma cells for treatment of relapsed/refractory neuroblastoma using an adenoviral vector
19. IL-2 adenovectortransduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma
20. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma
21. Progress reports on immune gene therapy for stage IV renal cell cancer using lethally irradiated granulocyte-macrophage colony-stimulating factor-transduced autologous renal cancer cells
22. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
23. Adenovector engineered interleukin-2 expressing autologous plasma cell vaccination after high-dose chemotherapy for multiple myeloma-a phase 1 study
24. Gene therapy of malignant gliomas: A pilot study of vaccination with irradiated autologous glioma and dendritic cells admixed with IL-4 transduced fibroblasts to elicit an immune response
25. Gene therapy of malignant gliomas: A phase I study of IL-4-HSV-TK gene-modified autologous tumor to elicit an immune response
26. Injection of colon carcinoma patients with autologous irradiated tumor cells and fibroblasts genetically modified to secrete interleukin-2 (IL2): A phase I study
27. Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas
28. Interleukin-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHC-restricted autologous lymphocytes
29. + cytotoxic T lymphocytes in vitro
30. Enhanced tumor protection by granulocyte-macrophage colony-stimulating factor expression at the site of an allogeneic vaccine
31. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens
32. Adenoviral transfer of xenogeneic MHC class I gene results in loss of tumorigenicity and inhibition of tumor growth
33. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants
34. Immunotherapy of experimental metastases by vaccination with interleukin genetransduced adenocarcinoma cells sharing tumor-associated antigens. Comparison between IL-12 and IL-2 gene-transduced tumor cell vaccines
35. IL-12 gene therapy for cancer: In synergy with other immunotherapies
36. Cancer vaccines: The interleukin 2 dosage effect
37. Type 1 versus type 2 cytokine release by Vbeta T cell subpopulations determines in vivo antitumor reactivity: IL-10 mediates a suppressive role
38. Regulation of T-helper-1 versus T-helper-2 activity and enhancement of tumor immunity by combined DNA-based vaccination and nonviral cytokine gene transfer
39. Cytokine therapy for cancer
40. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
41. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
42. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma